NCT07110051Recruiting
Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient
Comparative Study Between Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient
Source: ClinicalTrials.gov · Last updated 11 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In current study the investigators aim to compare between nalbuphine versus tramadol for post-operative pain control in abdominal surgeries in pediatric.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 31 Jul 2025
- Start date
- 15 Jan 2025
- Primary completion date
- 15 Sept 2025
- Lead sponsor
- National Cancer Institute, Egypt
- Diseases
- Childhood cancers
- NCT number
- NCT07110051
What you commit to
- Study type: Interventional
- Planned participants: 128
- From 15 Jan 2025 to the primary completion date, 15 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient with previous chronic pain on opioids
Other illness
- Allergy from Tramal or nalbuphine
Other
- child guardian refusal.
Who the study is looking for
- Participants will be children aged 3-12 years
- American society of anesthesia (ASA) classification I-III.
- scheduled for elective Abdominal surgery under general anesthesia
Age in the registry: 3 years to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.